Medical devices

Home-grown companies say the American market is as attractive as ever, even with import duties hurting margins

It still projects full-year 2026 comparable sales growth of 6.5% to 7.5%

Singapore will also apply for full Medical Device Single Audit Program membership

Group’s proposed listing will serve as a springboard to accelerate regional expansion, with Indonesia as the sole overseas focus for now

To drive its post-listing performance, the company should educate investors, lay out operational milestones and emphasise its competitive advantage

It is offering 112.1 million shares at US$1.45 or S$1.892 apiece; this includes 5.9 million shares for a retail tranche in Singapore

Three new joint labs will develop new capabilities for high-value sectors such as aerospace and semiconductors

Singapore is not being ruled out as a potential listing location as the company seeks to tap its largest market

The new plant is the company’s largest in the region